Corindus Vascular Robotics entered into a definitive merger agreement to be acquired by Siemens Healthineers AG for an aggregate purchase price of approximately $1.1 billion.
Ophthalmic medical technology and pharmaceutical company Glaukos Corp. will acquire hybrid ophthalmic pharma and medical tech company Avedro Inc. in an all-stock transaction.
Shares of Cambrex Corp. were up more than 46 percent in trading after the company announced an agreement to be acquired by an affiliate of the Permira funds for $60 per share, totaling $2.4 billion.
Sanofi Reports Strong Second-Quarter 2019
Acquisitions, Analysts, Asthma, Atopic Dermatitis (Eczema), Business, China, Chronic Rhinosinusitis, Diabetes, Earnings per share (EPS), European Medicines Agency, FDA, Future Blockbusters, Hemophilia, Insulin, Product Launches, Profitability, Quarterly results, R&D, Relapse/Refractory Multiple Myeloma, VaccinesSanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
Roche lifted the company’s full-year sales outlook after revenue in first-half 2019 rose 18 percent, helped by newer drugs including the MS medicine Ocrevus and the cancer immunotherapy Tecentriq.
Illinois-based AbbVie announced that the company will acquire Ireland-based Allergan for $63 billion in a cash and stock deal.
Bristol-Myers plans to divest Celgene’s psoriasis drug
Acquisitions, Analysts, Autoimmune Diseases, Autoimmune Disorders, Blockbusters, Business, Cancer, European Commission, Immunology, M&A, Plaque Psoriasis, Psoriasis, Shares, Stocks, Tyrosine Kinase 2 Inhibitors, U.S. Federal Trade Commission (FTC)Bristol-Myers Squibb Co. offered to divest Celgene Corp.’s psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.
UnitedHealth Group Inc. won anti-trust approval to buy DaVita Inc.’s primary and urgent care unit for $4.3 billion, the Federal Trade Commission said.
Contract research organization Catalent plans to buy Bristol-Myers Squibb’s manufacturing and packaging factory in Anagni, Italy, used to manufacture oral solid, biologics and sterile products.
Merck agreed to acquire Tilos, a privately held biopharma company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.
